Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Flisom Raises Funding to Ramp Up 15 MW Flexible CIGS Production Plant

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
Flisom closes 3rd funding round and signs R&D collaboration agreement with Empa.

Flisom has raised a substantially large investment to further develop its technology and build a production plant with an annual capacity of 15MW in Switzerland.

Besides securing financial backing, Flisom also signed an agreement with Empa, the Swiss Federal Laboratories for Materials Science and Technology, to provide research and development support on high-efficiency flexible CIGS solar cell technology.

Flisom’s third funding round was completed with participation from a Swiss investor along with Flisom’s existing strategic investor, Tata, India’s largest and most respected business house.

“This new investment marks investors’ satisfaction with Flisom’s progress towards the development of industrial manufacturing technology for roll-to-roll production of flexible solar modules. The 15MW plant will serve as a blueprint towards the establishment of larger-scale plants to manufacture flexible solar modules at low cost”, says Flisom’s interim CEO Marc Kaelin. “Flisom’s technology shows strong potential in helping solar electricity become affordable.”

“At Tata, we are keen to support the company in achieving its vision. Such technologies have a potential to transform many lives for the better”, adds K.R.S. Jamwal, Executive Director, Tata Industries. “We admire the team and technology, based on a record setting efficiency of over 20% for CIGS from Empa, which we hope will be scaled up successfully. The funding will enable Flisom to purchase equipment and hire more experts to convert an innovative Swiss technology into an industrial reality.”

Flisom’s high performance products, processes and systems could lower the price of solar electricity thanks to low material usage, economic production technology, and reduced storage, transportation and installation costs.

Markets addressable by Flisom’s flexible solar module manufacturing technology include utility scale solar farms, building integrated photovoltaics (BIPV), building applied photovoltaics (BAPV), transportation, portable power and electronics.

The key is roll-to-roll manufacturing

The production technology is roll-to-roll manufacturing of flexible solar modules, involving deposition of CIGS thin films onto polymer foil. Founded as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology Zurich), Flisom has subsequently developed proprietary tools and processes for manufacturing solar modules.

After moving to Empa’s Dübendorf campus, Flisom has been collaborating with Empa’s Laboratory for Thin Films and Photovoltaics led by Ayodhya Nath Tiwari through various projects.

On 17 January 2013, Empa announced that its CIGS flexible solar cells achieved 20.4% photovoltaic conversion efficiency - a world record for CIGS technology that equals the record efficiency of polycrystalline Si wafer solar cells.

“Scale-up for large-area solar modules and adapting these complex innovative processes for industrial manufacturability is quite a challenge and requires close collaboration between research labs and industrial partner”, says Pierangelo Groening, head of the Department of Advanced Materials and Surfaces and member of the Board of Directors at Empa.

“Therefore, Empa and Flisom have signed a collaboration agreement on certain topics of flexible CIGS technology, and Empa has deputed Tiwari for a part-time involvement as senior strategic officer to support Flisom’s further development, a move that is instrumental to Empa’s long-term strategy to support early-stage companies with global market ambitions. This is a very special way of technology transfer - by way of sharing highly experienced staff. We expect Flisom to benefit greatly from Ayodhya Tiwari’s expert knowledge and experience. I see it as sort of a kick-start for the company’s new phase of development”, says Empa CEO, Gian-Luca Bona.

“The success also highlights, according to Bona, Empa’s strength in the field of renewable energy and, in particular, photovoltaics. We have several labs here at Empa devoted to the development of various innovative thin film technologies for solar energy generation”, he says.

“Along with the success of Flisom’s capital raise, we are very impressed by the high photovoltaic conversion efficiency attained by our scientific partners at Empa”, says Flisom interim CEO Kaelin.

Kaelin continued, “We look forward to benefitting from the insights of Empa to further raise the efficiency of flexible solar modules produced using Flisom’s industrial roll-to-roll vacuum deposition technology.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos